One of the world’s top fund managers is backing volatile healthcare stocks VRX and MNKD.
MannKind Corporation (NASDAQ:MNKD) could be ready to capture an enticing amount of diabetes market share despite what the Street mostly dismissed as a …
H.C.
It was a bad day to be a MannKind Corporation (NASDAQ:MNKD) investor yesterday after the biotech stock took an around 8% beating in the …
Jason Kolbert recently downgraded MNKD on cash flow concerns; after this Q3 print, looks like he was right.
Both TRXC and MNKD offer potentially big rewards, but at what cost?
MannKind’s capital raise is not enough, says Jason Kolbert.
Oren Livnat believes MNKD’s revised debt arrangements will be advantageous to the Afrezza launch.
MannKind Corporation (NASDAQ:MNKD) and BIOMM announced the submission of a registration dossier to ANVISA, seeking the approval of Afrezza® (insulin human) inhalation powder …
MannKind Corporation (NASDAQ:MNKD) shares inched lower on Wednesday after rising to 52-week highs in the previous session. The reason?
